Skip to main content

Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity.

Publication ,  Journal Article
Maglalang, PD; Sinha, J; Helfer, VE; Edginton, A; Zimmerman, K; Hornik, CD; Muller, WJ; Rathore, M; Benjamin, DK; Chen, J-Y; Anand, R ...
Published in: J Clin Pharmacol
September 29, 2025

Oxcarbazepine (OXC) is a second-generation antiseizure medication, effective through its active metabolite, 10-mono-hydroxy derivative (MHD). OXC is used as adjunctive therapy for focal-onset and primary generalized tonic-clonic seizures, with recommended dosing based on age and body weight. This study uses physiologically based pharmacokinetic (PBPK) modeling and leverages pharmacokinetic (PK) data acquired from children enrolled in pragmatic trials to understand dosing and subsequent exposure requirements in children with obesity. Drug concentrations of OXC and MHD (n = 148 each) from children with (n = 31) and without (n = 10) obesity, aged 2-20 years, were collected from two clinical trials (NCT01431326 and NCT02993861) and used for external evaluation of a previously developed PBPK model of OXC using PK-Sim. We used a previously published virtual population that accounts for the obesity-related changes in physiology (e.g., liver size and glomerular filtration rate) in children for PK simulations in children with obesity. Model evaluation showed that ≥80% of MHD concentrations contributed by about two thirds of study subjects (26 out of 41) fell within the 90% prediction interval. The PBPK model showed that children with obesity had lower median (interquartile range) simulated weight-normalized clearance (0.060 L/h/kg [0.048-0.076 L/h/kg]) than children without obesity (0.067 L/h/kg [0.060-0.077 L/h/kg]). Simulations revealed that the recommended pediatric dosing regimen produced comparable MHD exposure between children with and without obesity at steady state, supporting its applicability regardless of obesity status. This PBPK-based dosing aligns with product label recommendations and demonstrates the potential of PBPK modeling for dosing other drugs in children with obesity.

Duke Scholars

Published In

J Clin Pharmacol

DOI

EISSN

1552-4604

Publication Date

September 29, 2025

Location

England

Related Subject Headings

  • Pharmacology & Pharmacy
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Maglalang, P. D., Sinha, J., Helfer, V. E., Edginton, A., Zimmerman, K., Hornik, C. D., … Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. (2025). Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity. J Clin Pharmacol. https://doi.org/10.1002/jcph.70107
Maglalang, Patricia D., Jaydeep Sinha, Victόria Etges Helfer, Andrea Edginton, Kanecia Zimmerman, Chi Dang Hornik, William J. Muller, et al. “Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity.J Clin Pharmacol, September 29, 2025. https://doi.org/10.1002/jcph.70107.
Maglalang PD, Sinha J, Helfer VE, Edginton A, Zimmerman K, Hornik CD, et al. Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity. J Clin Pharmacol. 2025 Sep 29;
Maglalang, Patricia D., et al. “Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity.J Clin Pharmacol, Sept. 2025. Pubmed, doi:10.1002/jcph.70107.
Maglalang PD, Sinha J, Helfer VE, Edginton A, Zimmerman K, Hornik CD, Muller WJ, Rathore M, Benjamin DK, Chen J-Y, Anand R, Gonzalez D, Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity. J Clin Pharmacol. 2025 Sep 29;

Published In

J Clin Pharmacol

DOI

EISSN

1552-4604

Publication Date

September 29, 2025

Location

England

Related Subject Headings

  • Pharmacology & Pharmacy
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences